Bryan Garnier - SOMFY (DAMA.PA) SOMFY: Buoyant Q3 revenues | BUY - Top Picks | EUR105 vs. EUR100 (+27%)

Report

Bryan Garnier

Eric Lemarie

SOMFY: Buoyant Q3 revenues | BUY - Top Picks | EUR105 vs. EUR100 (+27%)

SOMFY - BUY - Top Picks | EUR105 vs. EUR100 (+27%)
Buoyant Q3 revenues

Acceleration of growth in Q3
â€˜Reflecting success of partnerships and innovationsâ€™, says Somfy
Double-digit organic growth in five zones in Q3 (c60% of sales)
5% organic growth likely to be exceeded this year.

18/10/2019 4 EN

Underlying

SOMFY

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Eric Lemarie

Other Reports on these Companies

Bryan Garnier

SOMFY: Better 1H22 margin than expected, attractive valuation despite weakening demand | BUY | EUR155

SOMFY - BUY | EUR155 Better 1H22 margin than expected, attractive valuation despite weakening demand Margins proved more resilient than expected in 1H22 despite lower 2Q22 demand As expected, volumes should remain negatively oriented in 2H22 BUY reiterated, TP EUR155

September 8, 2022 September 8, 2022 1 EN

Bryan Garnier

SOMFY BUY | EUR155 Lower than expected Q2 sales: the storm is coming earlier and stronger than expected

º Negative organic growth in Q2, an unexpected -6% volume decline Growth outlook significantly deteriorating

July 22, 2022 July 22, 2022 1 EN

Bryan Garnier

TECHNOLOGY Excessive relative derating for Schneider and Somfy

As a summary of the 1Q22 publications of our industrial coverage, we believe Schneider features the best fundamentals given (i) its strong industry automation focus, (ii) a product portfolio resolutely focused on sustainability and resource frugality in a context of tense supply chains, and (iii) its diversified geographical exposure. Schneider’s valuation, at par with building-focused players, is in our view not justified given its better fundamentals. Regarding Legrand and Somfy, players almost exclusively addressing the building sector, we believe Somfy’s valuation discount over Legrand is ...

May 24, 2022 May 24, 2022 1 EN

Valneva : Strong H1 - Key Lyme vaccine catalyst ahead in Q4

Valneva delivered a solid H1 and reaffirmed its 2025 guidance. The company’s cash position, standing at €161m, is sufficient to fund operations through 2027e, providing solid financial visibility. Looking ahead, the next key catalyst is the Phase III data readout for VLA15, Valneva’s Lyme disease v

18h / 56m 18h / 56m 1 EN

Clément Genelot

Clément Genelot

Deliveroo: strengthening growth/margin profile ahead of DoorDash deal

Post-another strong print and FY guidance upgrade, fuelled by a recovery in order growth and market share gains, we see more credibility in Deliveroo's MT targets and have increased our EBITDA and FCF estimates by 8% and 11%. PT unchanged at 180p to stick to the DoorDash offer, which we view as fai

August 8, 2025 August 8, 2025 1 EN

Damien Choplain ... (+2)

Damien Choplain
Oscar Haffen Lamm

Valneva : FDA lifts age restriction on IXCHIQ

Valneva announced yesterday that the FDA has lifted its recommended pause on the use of IXCHIQ in individuals aged 60+, following updated safety data. This follows a similar decision by the EMA in July, which lifted temporary restrictions after a safety review. Despite regulatory clearance from bot

August 8, 2025 August 8, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

SOMFY: Buoyant Q3 revenues | BUY - Top Picks | EUR105 vs. EUR100 (+27%)

SOMFY: Better 1H22 margin than expected, attractive valuation despite weakening demand | BUY | EUR155

SOMFY BUY | EUR155 Lower than expected Q2 sales: the storm is coming earlier and stronger than expected

TECHNOLOGY Excessive relative derating for Schneider and Somfy

Valneva : Strong H1 - Key Lyme vaccine catalyst ahead in Q4

Deliveroo: strengthening growth/margin profile ahead of DoorDash deal

Valneva : FDA lifts age restriction on IXCHIQ

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe